Abstract
Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Volume: 11 Issue: 1
Author(s): Wei-Hua Yan
Affiliation:
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Abstract: Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Export Options
About this article
Cite this article as:
Yan Wei-Hua, HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187153011794982059
DOI https://dx.doi.org/10.2174/187153011794982059 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advantages of Multidetector CT Cystoscopy in the Detection of Bladder Tumors
Current Medical Imaging The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer
Mini-Reviews in Medicinal Chemistry Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Current Gene Therapy Diselenides and Selenocyanates as Versatile Precursors for the Synthesis of Pharmaceutically Relevant Compounds
Current Organic Synthesis Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms
Current Topics in Medicinal Chemistry Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging
Current Medicinal Chemistry Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design